Videos

Peter J. Polack, MD, FACS, and Zora Harrison, COO at Ocala Eye, share the protocols and technology their practice implemented throughout the pandemic that has enabled them to safely and efficiently treat their patients.

Rachel Curtis, MD, a fourth-year resident at Queen's University, Kingston, Ontario, Canada, discusses the highlights from a study comparing a smartphone-compatible device versus traditional direct ophthalmoscopy in teaching medical students how to complete an optic nerve examination.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Kuldev Singh, MD, MPH, professor/director of the Glaucoma Service Stanford Medical Center, shares the highlights from his discussion on surgical procedure decision-making in the era of MIGS.

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, provides an update on optimization and surgical modifications of newer glaucoma surgeries.

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Andrew Iwach, MD, and Adrienne Graves, PhD, co-founders of Glaucoma 360, preview what attendees will experience at the 2021 version of the CME/CE Symposia, Annual Gala, and New Horizons Forum.